Marker Therapeutics

12 articles about Marker Therapeutics

• Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse

  9/11/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.

• Marker Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference

  8/30/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR) today announced that Juan F. Vera, M.D., President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference, which is being held on September 11-13, 2023 at the Lotte New York Palace Hotel in New York City.

• Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

  8/14/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today reported corporate updates and financial results for the second quarter ended June 30, 2023.

• Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program

  8/7/2023

  Marker Therapeutics, Inc. today announced non-clinical data of its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, in an Off-the-Shelf (OTS) setting and provided an update on clinical readiness for the OTS program.

• Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023

  7/26/2023

  Marker Therapeutics, Inc. today announced participation in a live webcast produced by Demy-Colton and sponsored by the WBB Research Institute titled “Beyond CAR-T, What’s Next for Cell Therapy”.

• European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients

  7/10/2023

  Marker Therapeutics, Inc. (Nasdaq: MRKR) announced that zedenoleucel, its multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, was granted Orphan Drug Designation by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) for the treatment of patients with acute myeloid leukemia (AML).

• Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration

  6/26/2023

  Marker Therapeutics, Inc. today reports non-clinical data on its lead multi-tumor-associated antigen (multiTAA)-specific T cell product candidate, MT-401, which showed increased anti-tumor activity against an acute myeloid leukemia (AML) cell line after treatment with hypomethylating agents (HMA).

• Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial

  6/12/2023

  Marker Therapeutics, Inc. announced that the first patient has been treated in the company sponsored Phase 1 multicenter APOLLO trial investigating MT-601, a multi-tumor-associated antigen -specific T cell product targeting six antigens, for the treatment of patients with lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment.

• Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsMT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro

  5/31/2023

  Marker Therapeutics, Inc. announced pre-clinical data from the Company’s multiple tumor-associated antigens -specific T cell product candidate MT-601 in lymphoma cells, including CD19 CAR T refractory cells.

• Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer

  5/8/2023

  Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.

• Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

  5/1/2023

  Marker Therapeutics, Inc. today announced that it has entered into a comprehensive agreement with CellReady™, a newly formed Contract Development and Manufacturing Organization (CDMO) founded by John Wilson, founder and CEO of Wilson Wolf Corporation and Marker Co-Founder and Board Member.

• Marker Therapeutics Reports Fiscal Year 2022 Corporate and Financial Results

  3/22/2023

  Marker Therapeutics, Inc. today reported fiscal year 2022 financial results and provided updates for its clinical development programs.